Lipoxen enters accord to eliminate "cold chain"

Lipoxen, a UK bio-pharmaceutical company specializing in the development of high-value differentiated biologicals, vaccines and oncology drugs, has entered into a research agreement with Cambridge Biostability, the University of Cambridge and the Health Protection Agency to develop a novel vaccine technology, which will achieve greater efficacy and eliminate the need for "cold-chain" distribution methods.

Under the research accord, the parties will be working to create vaccine materials that are more stable, have a long shelf-life, require fewer doses in order to be effective and overcome the cold-chain storage and distribution problem associated with traditional products. The firm says vaccines with these novel attributes would represent a major advance, particularly for people in the developing world who are unnecessarily dying from diseases that can be prevented through more efficient delivery and storage of vaccinations.